| Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management |
25 |
| A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis |
21 |
| Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis |
16 |
| Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study |
13 |
| Rising Proportion of Young Individuals With Rectal and Colon Cancer |
13 |
| A Review on the Scope of Photothermal Therapy-Based Nanomedicines in Preclinical Models of Colorectal Cancer |
13 |
| A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study |
13 |
| Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States |
12 |
| Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer |
12 |
| c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival |
11 |
| Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis |
11 |
| Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients |
10 |
| Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery |
10 |
| Efficacy of Mobile Health Care Application and Wearable Device in Improvement of Physical Performance in Colorectal Cancer Patients Undergoing Chemotherapy |
10 |
| Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation? |
10 |
| Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales |
10 |
| Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer |
10 |
| Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group |
9 |
| Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies |
9 |
| Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review |
9 |
| Evidence Suggests Sphingosine 1-Phosphate Might Be Actively Generated, Degraded, and Transported to Extracellular Spaces With Increased S1P(2) and S1P(3) Expression in Colon Cancer |
9 |
| 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer |
8 |
| Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice |
8 |
| Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial |
8 |
| Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing |
8 |
| Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics |
8 |
| Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer |
8 |
| Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients |
8 |
| Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer |
8 |
| A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND. a Canadian Cancer Trials Group Trial |
8 |
| Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up |
8 |
| Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial |
7 |
| Is Cure Possible After Sequential Resection of Hepatic and Pulmonary Metastases From Colorectal Cancer? |
7 |
| Effect of Primary Tumor Location on Second-or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies |
7 |
| FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data |
7 |
| Cancer Stemness, Immune Cells, and Epitheliale-Mesenchymal Transition Cooperatively Predict Prognosis in Colorectal Carcinoma |
7 |
| Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer |
7 |
| Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine |
7 |
| Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials |
7 |
| Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib |
6 |
| Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal |
6 |
| Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma |
6 |
| Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis |
6 |
| Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study |
6 |
| Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer |
6 |
| Review: Pathology and Its Clinical Relevance of Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei |
6 |
| LGALS CEACAM TSPAN and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result |
6 |
| Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study |
6 |
| Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection |
6 |
| Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes |
6 |
